Abstract Details
|
Yuishin Izumi, MD, PhD
PRESENTER |
No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| Masaki Kamada, MD (Kagawa Unuversity) | No disclosure on file |
| No disclosure on file | |
| Stanley H. Appel, MD, FÂ鶹´«Ã½Ó³» (Methodist Neurological Institute) | Dr. Appel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Appel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eledon. The institution of Dr. Appel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Implicit. The institution of Dr. Appel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Coya Therapeutics. Dr. Appel has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Muscular Disease Association. Dr. Appel has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for ALS Therapy Development Institute. Dr. Appel has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for ALS Finding a Cure. Dr. Appel has stock in Stock holdings in retirement acct at Fidelity. The institution of Dr. Appel has received research support from Coya Therapeutics. |
| Ryosuke Miyamoto, MD | No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Hiroyuki Nodera, MD (Beth Israel Deaconess Med Ctr) | No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| Ryuji Kaji, MD, FÂ鶹´«Ã½Ó³» (Tokushima University Graduate School of Medicine) | Dr. Kaji has nothing to disclose. |